A Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of elitercept (KER-050) in the treatment of transfusion-dependent anemia in adult participants with very low-risk, low, or intermediate risk (RENEW).

Principal Investigator

Dott.ssa Elena Crisà

Contact Information for Access

• elena.crisa@inoc.it
• simone.morabito@inoc.it
• ufficio.trials@inoc.it

Phase

FASE III

Status

ATTIVO

---

Objective of the study

The primary objective of this study is to determine the effectiveness of elitercept in reducing the need for red blood cell transfusions. Other objectives include evaluating the effectiveness of elitercept in reducing the need for red blood cell transfusions over extended periods of time or in adults with high transfusion requirements. The study will also assess the safety and tolerability of elitercept.

Myelodysplastic Syndrome.

ClinicalTrials.gov ID NCT06499285
Sponsor: Takeda

Pathologies

Onco-hematological (hematological cancers/malignancies)

Medication

Elritercept vs. Placebo (blinded).

Who is eligible to participate in the study?

Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Anemic, transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndrome

View the full study Back to search page